Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 8/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21710432 | 0.93 | RORC (0.43) | RORCUSP2SMN1; SMN2 | |
| SCHEMBL26066372 | 0.86 | USP2 (0.39) | USP2SMN1; SMN2GPR119AVPR1AESR2 | |
| SCHEMBL1805309 | 0.86 | OPRL1 (0.48) | — | |
| SCHEMBL1810886 | 0.86 | OPRL1 (0.48) | RORCUSP2SMN1; SMN2ESR2 | |
| SCHEMBL23192562 | 0.85 | USP2 (0.39) | USP2SMN1; SMN2GPR119AVPR1AESR2 | |
| SCHEMBL18590704 | 0.82 | RORC (0.38) | RORCUSP2SMN1; SMN2GPR119SCD5 | |
| SCHEMBL21710542 | 0.82 | RORC (0.38) | RORCUSP2SMN1; SMN2GPR119SCD5 | |
| SCHEMBL20487525 | 0.81 | RORC (0.45) | RORC | |
| SCHEMBL1807425 | 0.80 | OPRL1 (0.47) | RORCUSP2SMN1; SMN2GPR119AVPR1A | |
| SCHEMBL21710521 | 0.78 | RORC (0.70) | RORCGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110337440-B | Compounds useful for inhibition of ROR-gamma-t | 伊莱利利公司 | 2021-08-03 | — | — | CN | disclosed |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| CN-108026112-B | Compounds for inhibition of ROR-gamma-T | 伊莱利利公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY | 2020-02-13 | — | — | US | disclosed |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY | 2020-02-13 | — | — | US | disclosed |
| EP-3347360-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3347360-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018160550-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
| US-9598431-B1 | Compounds useful for inhibiting ROR-gamma-t | ELI LILLY AND COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598431-B1 | Compounds useful for inhibiting ROR-gamma-t | ELI LILLY AND COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598431-B1 | Compounds useful for inhibiting ROR-gamma-t | ELI LILLY AND COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2017044410-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066781-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | RORC 1/4885USP2 2526/4885SMN1; SMN2 4475/4885 |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | RORB, RORC, RORA | RORC 2/4885USP2 3449/4885SMN1; SMN2 4789/4885 |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | RORC 1/4885USP2 3407/4885SMN1; SMN2 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.